Published in Clin Nutr on October 01, 1992
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev (2009) 3.08
Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) (2010) 1.28
Advanced materials and processing for drug delivery: the past and the future. Adv Drug Deliv Rev (2012) 1.14
Low molecular-weight chitosan as a pH-sensitive stealth coating for tumor-specific drug delivery. Mol Pharm (2012) 1.00
Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv (2013) 0.99
Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. ACS Nano (2014) 0.92
Enhancing therapeutic efficacy through designed aggregation of nanoparticles. Biomaterials (2014) 0.80
The effect of polymer backbone chemistry on the induction of the accelerated blood clearance in polymer modified liposomes. J Control Release (2015) 0.80
Targeted Nanotherapies for the Treatment of Surgical Diseases. Ann Surg (2016) 0.78
Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev (2004) 2.10
Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int J Pharm (2000) 1.73
Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J Biomed Mater Res (1998) 1.51
Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm (1999) 1.42
Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm (2004) 1.37
Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis (1993) 1.27
Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. J Control Release (2002) 1.17
Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials (1999) 1.16
A novel assay to determine the hemolytic activity of drugs incorporated in colloidal carrier systems. Pharm Res (1994) 1.06
Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm (2000) 1.05
Importance of the fraction of microcrystalline cellulose and spheronization speed on the properties of extruded pellets made from binary mixtures. Pharm Dev Technol (1999) 1.03
Increasing drug solubility by means of bile salt-phosphatidylcholine-based mixed micelles. Eur J Pharm Biopharm (1998) 1.02
Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles. Int J Pharm (2001) 1.02
Cosmetic features and applications of lipid nanoparticles (SLN, NLC). Int J Cosmet Sci (2008) 1.01
In vivo gene delivery to the lung using polyethylenimine and fractured polyamidoamine dendrimers. J Gene Med (2000) 1.01
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother (2000) 1.01
Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother (2001) 0.99
Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int J Pharm (2005) 0.99
Influence of supersaturation on the pharmacodynamic effect of bupranolol after dermal administration using microemulsions as vehicle. Pharm Res (1992) 0.98
Solubility and stability of lorazepam in bile salt/soya phosphatidylcholine-mixed micelles. Drug Dev Ind Pharm (1999) 0.98
Nanosuspensions of poorly soluble drugs--reproducibility of small scale production. Int J Pharm (2000) 0.98
Solubility and stability of tetrazepam in mixed micelles. Eur J Pharm Sci (1998) 0.98
Investigation on the viscoelastic properties of lipid based colloidal drug carriers. Int J Pharm (2000) 0.97
Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption. Pharm Res (1999) 0.97
A rapid and quantitative method for total fatty acid analysis of fungi and other biological samples. Lipids (1999) 0.96
Beta-carotene-loaded nanostructured lipid carriers. J Food Sci (2008) 0.96
Plasma protein adsorption on biodegradable microspheres consisting of poly(D,L-lactide-co-glycolide), poly(L-lactide) or ABA triblock copolymers containing poly(oxyethylene). Influence of production method and polymer composition. J Control Release (1998) 0.96
Production of drug loaded microparticles by the use of supercritical gases with the aerosol solvent extraction system (ASES) process. J Microencapsul (1997) 0.95
Solid lipid nanoparticles (SLN)--a novel carrier for UV blockers. Pharmazie (2001) 0.95
Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. Int J Pharm (2011) 0.95
A novel sunscreen system based on tocopherol acetate incorporated into solid lipid nanoparticles. Int J Cosmet Sci (2001) 0.94
Solid lipid nanoparticles (SLN/Lipopearls)--a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J Microencapsul (2000) 0.93
Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. Int J Pharm (2001) 0.93
Effect of hydroxypropyl-beta-cyclodextrin on the antimicrobial action of preservatives. J Pharm Pharmacol (1994) 0.92
Influence of different parameters on reconstitution of lyophilized SLN. Int J Pharm (2000) 0.92
Physico-chemical characterization of interactions between erythromycin and various film polymers. Int J Pharm (1999) 0.92
Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC. J Microencapsul (2006) 0.91
Protein rejecting properties of PEG-grafted nanoparticles: influence of PEG-chain length and surface density evaluated by two-dimensional electrophoresis and bicinchoninic acid (BCA)-proteinassay. Pharmazie (2006) 0.90
Adsorption kinetics of plasma proteins on ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles. Int J Pharm (2012) 0.90
SLN and NLC for topical delivery of ketoconazole. J Microencapsul (2005) 0.90
Properties of ibuprofen crystallized under various conditions: a comparative study. Drug Dev Ind Pharm (2002) 0.90
Pharmacodynamic effects of transdermal bupranolol and timolol in vivo: comparison of microemulsions and matrix patches as vehicle. Methods Find Exp Clin Pharmacol (1991) 0.90
The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer--poloxamine 908. Life Sci (1987) 0.89
Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release (2001) 0.89
Formulation of intravenous carbamazepine emulsions by SolEmuls technology. Eur J Pharm Biopharm (2003) 0.89
Interaction of bronchoalveolar lavage fluid with polyplexes and lipoplexes: analysing the role of proteins and glycoproteins. J Gene Med (2003) 0.89
Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm (2002) 0.89
Production and characterisation of highly concentrated nanosuspensions by high pressure homogenisation. Int J Pharm (2001) 0.88
Identification of plasma proteins facilitated by enrichment on particulate surfaces: analysis by two-dimensional electrophoresis and N-terminal microsequencing. Electrophoresis (1997) 0.87
Stability determination of solid lipid nanoparticles (SLN) in aqueous dispersion after addition of electrolyte. J Microencapsul (1999) 0.87
The use of SLN and NLC as topical particulate carriers for imidazole antifungal agents. Pharmazie (2006) 0.86
Determination of plasma protein adsorption on magnetic iron oxides: sample preparation. Pharm Res (1997) 0.86
Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages. Biomaterials (1987) 0.85
Liquid and semisolid SLN dispersions for topical application: rheological characterization. Eur J Pharm Biopharm (2004) 0.85
Nanostructured lipid carriers as novel carrier for sunscreen formulations. Int J Cosmet Sci (2007) 0.85
Two-time window and multiangle photon correlation spectroscopy size and zeta potential analysis--highly sensitive rapid assay for dispersion stability. J Pharm Sci (2000) 0.84
Hydroxypropyl-beta-cyclodextrin derivatives: influence of average degree of substitution on complexing ability and surface activity. J Pharm Sci (1986) 0.84
Skin moisturizing effect and skin penetration of ascorbyl palmitate entrapped in solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) incorporated into hydrogel. Pharmazie (2005) 0.84
Comparison of protein adsorption patterns onto differently charged hydrophilic superparamagnetic iron oxide particles obtained in vitro and ex vivo. Electrophoresis (2001) 0.84
Jet milling--a new technique for microparticle preparation. Int J Pharm (2002) 0.84
Novelty-elicited mismatch negativity in patients with schizophrenia on admission and discharge. J Psychiatry Neurosci (2001) 0.84
Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J Microencapsul (2006) 0.84
Cyclodextrin derivatives in pharmaceutics. Crit Rev Ther Drug Carrier Syst (1995) 0.83
Production & stability of stavudine solid lipid nanoparticles--from lab to industrial scale. Int J Pharm (2010) 0.83
Investigations into the pharmacodynamic effects of dermally administered microemulsions containing beta-blockers. J Pharm Pharmacol (1991) 0.83
Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int J Pharm (1999) 0.83
In vitro corneal permeability of diclofenac sodium in formulations containing cyclodextrins compared to the commercial product voltaren ophtha. J Pharm Sci (1994) 0.83
Jet nebulization of PEI/DNA polyplexes: physical stability and in vitro gene delivery efficiency. J Gene Med (2002) 0.83
Electrolyte- and pH-stabilities of aqueous solid lipid nanoparticle (SLN) dispersions in artificial gastrointestinal media. Eur J Pharm Biopharm (2001) 0.83
Size controlled production of biodegradable microparticles with supercritical gases. Eur J Pharm Biopharm (1998) 0.83
Physicochemical properties of chitosan-lipid emulsions and their stability during the autoclaving process. Int J Pharm (1999) 0.82
Interaction of prostaglandin E1 with alpha-cyclodextrin in aqueous systems: stability of the inclusion complex. J Pharm Sci (1991) 0.82
Solid lipid nanoparticles (SLN)--effects of lipid composition on in vitro degradation and in vivo toxicity. Pharmazie (2006) 0.82
Adsorption kinetics of plasma proteins on oil-in-water emulsions for parenteral nutrition. Eur J Pharm Biopharm (2000) 0.82
Semisolid SLN dispersions for topical application: influence of formulation and production parameters on viscoelastic properties. Eur J Pharm Biopharm (2002) 0.82
Physicochemical investigations on the structure of drug-free and drug-loaded solid lipid nanoparticles (SLN) by means of DSC and 1H NMR. Pharmazie (2005) 0.81
Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone. Int J Pharm (2001) 0.81
Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations. Eur J Pharm Biopharm (2004) 0.81
Skin photoprotection improvement: synergistic interaction between lipid nanoparticles and organic UV filters. Int J Pharm (2011) 0.81
The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression. Pharmacopsychiatry (2005) 0.81
The influence of the sample preparation on plasma protein adsorption patterns on polysaccharide-stabilized iron oxide particles and N-terminal microsequencing of unknown proteins. J Drug Target (1997) 0.81
Resveratrol nanosuspensions for dermal application--production, characterization, and physical stability. Pharmazie (2009) 0.81
A novel approach based on lipid nanoparticles (SLN) for topical delivery of alpha-lipoic acid. J Microencapsul (2005) 0.80
Influence of surfactants on the physical stability of solid lipid nanoparticle (SLN) formulations. Pharmazie (2004) 0.80
Influence of the acid type on the physical and drug liberation properties of chitosan-gelatin sponges. Int J Pharm (2000) 0.80
Expression of the 2,4-D degradative pathway of pJP4 in an alkaliphilic, moderately halophilic soda lake isolate, Halomonas sp. EF43. Extremophiles (2001) 0.80
Analysis of plasma protein adsorption onto polystyrene particles by two-dimensional electrophoresis: comparison of sample application and isoelectric focusing techniques. Electrophoresis (2000) 0.80
The influence of alkali fatty acids on the properties and the stability of parenteral O/W emulsions modified with solutol HS 15. Eur J Pharm Biopharm (2000) 0.80
Determination of liposome partitioning of ionizable drugs by titration. J Pharm Sci (1999) 0.79
Rheology of nanostructured lipid carriers (NLC) suspended in a viscoelastic medium. Pharmazie (2005) 0.79
smartCrystal combination technology--scale up from lab to pilot scale and long term stability. Pharmazie (2010) 0.79
SolEmuls technology: a way to overcome the drawback of parenteral administration of insoluble drugs. Pharm Dev Technol (2007) 0.79
Piroxicam release from spray-dried biodegradable microspheres. Biomaterials (1994) 0.79
Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. J Microencapsul (2001) 0.79
Complexation of steroid hormones with cyclodextrin derivatives: substituent effects of the guest molecule on solubility and stability in aqueous solution. J Pharm Sci (1992) 0.79
Modified Rose Bengal assay for surface hydrophobicity evaluation of cationic solid lipid nanoparticles (cSLN). Eur J Pharm Sci (2012) 0.79
Lipid emulsions as a novel system to reduce the hemolytic activity of lytic agents: mechanism of the protective effect. Eur J Pharm Sci (2000) 0.79
Effect of solid lipid nanoparticles (SLN) on cytokine production and the viability of murine peritoneal macrophages. J Microencapsul (2001) 0.78